Progenics to initiate basket trial to support expanded label for AZEDRA (iobenguane I 131)
Progenics announced the Company has reached alignment with the FDA on the clinical development plan to pursue a tissue agnostic indication to support an expanded label for AZEDRA (iobenguane I 131) for treatment of patients with unresectable or metastatic neuroendocrine tumors. June 20, 2019